China US and many nations race to prepare Coronavirus vaccines it is turn of UK.
Oxford university to test its Coronavirus vaccines.
Oxford University’s coronavirus vaccine opens for clinical trial on humans
Mahesh LangaAHMEDABAD 28 MARCH 2020 11:18 ISTUPDATED: 28 MARCH 2020 11:18 IST
ChAdOx1 nCoV-19, the COVID-19 vaccine developed by Oxford, is based on an adenovirus vaccine vector and the SARS-CoV-2 spike protein.
As the world is grappling with thousands of deaths and lakhs of coronavirus-infected cases, there is some hope as the world’s top university Oxford has announced its vaccine is entering Phase 1 clinical trials in humans.
In a press release, University of Oxford stated that its researchers working in an unprecedented vaccine development effort to prevent COVID-19 have started screening healthy volunteers (aged 18-55) on Friday for their upcoming ChAdOx1 nCoV-19 vaccine trial in England’s Thames Valley. The vaccine based on an adenovirus vaccine vector and the SARS-CoV-2 spike protein is already in production but won’t be ready for some weeks still.
Although this is the second vaccine to enter Phase 1, Oxford’s ‘viral vectored’ technology is more established, compared to Moderna’s RNA vaccine, which was the first to enter Phase 1. No RNA vaccines are currently licensed for human use.